Abstract 77P
Background
Sexual dysfunction is of the most common late effects after cancer. Normative general population data on sexual health is essential for supporting the interpretation of patient-reported outcomes (PROMs) in cancer studies and clinical practice and can contribute to improve survivorship care. This study aims to provides age-, sex- and morbidity specific Norwegian normative values for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires; the Sexual Health Questionnaire QLQ-SHQ22, and the sexual domains of the breast modules QLQ-BR23/QLQ-BR45 inindividuals with and without history of cancer.
Methods
A nationwide general population sample stratified by sex and age (18–29, 30–39, 40–49, 50–59, 60–69, 70-79 years) was drawn from the Norwegian Population Register. Participants were notified through National online health services and postal mail. The survey included sociodemographic background, morbidity assessed bythe Self-Administered Comorbidity Questionnaire and sexual health assessed by the sexual health EORTC questionnaires.
Results
Of the 15,627 eligible individuals, 5,135 (33%) responded. Among these, 453 persons reported being diagnosed one or several times with cancer, and 4669 persons had no former history of cancer (breast, prostate, gynecological and others). Individuals with cancer scored significantly lower (p<0.01) on several functional scales: libido (scores 54 vs. 70), sexual functioning (45 vs 58), sexual enjoyment (67 vs 76), and for women femininity (65 vs. 84). The most prominent differences in symptoms were fatigue (32 vs 20) and worry of incontinence (27 vs. 9). Women and individuals with comorbidities had in general poorer sexual health, and differences were most pronounced in the youngest age groups.
Conclusions
The present study is the first to use normative EORTC data to compare sexual health in individuals with- and without cancer. Sexual health was in general significantly poorer in individuals with history of cancer compared to individuals without cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Randi Johansen Reidunsdatter.
Funding
Norwegian Cancer Society and Norwegian Breast Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
514P - Immunophenotypic profile of glioblastoma microenvironment: A cohort study
Presenter: Lidia Gatto
Session: Poster session 09
515P - A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
Presenter: Shu Zhou
Session: Poster session 09
516P - Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
Presenter: Kristi Beshiri
Session: Poster session 09
517P - Differentiating IDH-wildtype and IDH-mutant high grade gliomas with deep learning
Presenter: Katherine Hewitt
Session: Poster session 09